Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Sclerosis: early-phase trial registry
120 of 317 indexed Multiple Sclerosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #24 of 28,707 conditions by registered trial count.
317 US clinical trials · 120 currently recruiting · #24 of 28,707 conditions by registered trial count
Multiple Sclerosis: 317 US clinical trials tracked, 120 recruiting.
Multiple Sclerosis is the subject of 317 registered US clinical trials on ClinicalTrials.gov, 120 of them currently open to new participants. 41 are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most active sponsor is Biogen, running 13 of these trials.
Enrollment posture brief
Registry condition multiple-sclerosis
OPEN 120 | RECR 38% | LATE 41 | EARLY 74 | RANK #24 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Multiple Myeloma (38% recruiting · 441 trials)
Multiple Sclerosis lists 120 open slots (38% of 317 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Sclerosis recruits in line with its size-band peers.
120 of 317 indexed trials (37.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Sclerosis trials is spread across many organizations.
Biogen accounts for 13 of 317 trials (4.1%). 142 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Sclerosis enrolment sits around 61 participants.
Median target enrolment is 61 among the 316 trials that report a genuine target (sentinel values excluded). 181 of those (57.3%) plan for fewer than 100 participants.
-
Multiple Sclerosis research is mostly interventional.
231 interventional and 86 observational studies make up this index (72.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
317 total, page 4 of 7
Lifestyle Physical Activity Intervention for Persons Newly Diagnosed With Multiple Sclerosis
University of Illinois at Chicago
NCT06355804
Exercise Training, Cognition, and Mobility in Older Adults With Multiple Sclerosis
University of Illinois at Chicago
NCT05930821
A Study to Evaluate White Matter Hyperintensities in Migraine
Mayo Clinic
NCT05112289
MitoQ for Fatigue in Multiple Sclerosis (MS)
VA Office of Research and Development
NCT04267926
Serum Neurofilament Light in Multiple Sclerosis
Dent Neuroscience Research Center
NCT06282081
The Synergistic Effects of AIH and FES in Persons With MS
Shirley Ryan AbilityLab
NCT06413602
Cladribine Tablets After Treatment With Natalizumab (CLADRINA)
University of Texas Southwestern Medical Center
NCT04178005
WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis
Kessler Foundation
NCT05755061
Acute Effects of Walking Exercise on Brain Functioning in Multiple Sclerosis
Kessler Foundation
NCT06233370
A Study of Ocrelizumab in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis
Hoffmann-La Roche
NCT04075266
Safety of Bryostatin in Patients With MS
Robert Fox
NCT06190912
Wearables for the Bladder: an In-home Treatment Feasibility Pilot Study
University of California, San Francisco
NCT05715268
Investigating the Impact of Sex Hormones in Multiple Sclerosis
Milap Sandhu
NCT07081594
Tolebrutinib, a Brain-penetrant Bruton's Tyrosine Kinase Inhibitor, for the Modulation of Chronically Inflamed White Matter Lesions in Multiple Sclerosis
National Institute of Neurological Disorders and Stroke (NINDS)
NCT04742400
HOme-Based Self-management and COgnitive Training CHanges Lives (HOBSCOTCH) - Multiple Sclerosis (MS)
Dartmouth-Hitchcock Medical Center
NCT06145737
"HB-adMSCs for the Treatment of Patients With Multiple Sclerosis"
Hope Biosciences Research Foundation
NCT06800404
Oral FMT (Fecal Microbial Transplant) in Subjects with Multiple Sclerosis
Griffin Hospital
NCT04096443
Risk Perception in Multiple Sclerosis
Novartis Pharmaceuticals
NCT05528666
Therapy Optimization in Multiple Sclerosis (MS)
Teva Neuroscience
NCT00819000
The MS-LINK™ Outcomes Study
EMD Serono Research & Development Institute
NCT04735406
Oral Ponesimod Versus Teriflunomide In Relapsing MUltiple Sclerosis
Actelion
NCT02425644
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)
Teva Branded Pharmaceutical Products R&D
NCT00509145
Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
Sanofi
NCT01895335
Multi-center Database Registry to Study Thalamus Changes Using AI in MS
University at Buffalo
NCT03920995
The MURDOCK Study Community Registry and Biorepository Multiple Sclerosis Cohort
Duke University
NCT01723709
Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis
Biogen
NCT02219932
Oral Cladribine in Early Multiple Sclerosis (MS)
EMD Serono Research & Development Institute
NCT00725985
Prospective, Open-label Tolerability and Safety Monitoring Study of Novantrone in a Selected Cohort of Multiple Sclerosis Patients
EMD Serono
NCT00262314
Optical Coherence Tomography (OCT) Trial in Multiple Sclerosis
Novartis Pharmaceuticals
NCT02907281
A Study of the Safety and Efficacy of ONO-4641 in Patients With Relapsing-Remitting Multiple Sclerosis
Ono Pharma USA
NCT01081782
Pregnancy Exposure Registry for Tysabri®
Biogen
NCT00472992
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
RVL Pharmaceuticals
NCT01743651
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
RVL Pharmaceuticals
NCT03319732
CogMS - A Real-world Study Into Cognitive Impairment in People With Multiple Sclerosis
icometrix
NCT05671055
A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients
Novartis Pharmaceuticals
NCT03560739
Online Program to Reduce Depression in MS
Charite University, Berlin, Germany
NCT02740361
Study of Subcutaneous Daclizumab in Patients With Active, Relapsing Forms of Multiple Sclerosis
PDL BioPharma
NCT00109161
Characterizing Upper Extremity Function in Individuals With Multiple Sclerosis
Mount Sinai Rehabilitation Hospital
NCT02398149
Duloxetine for Multiple Sclerosis Pain
Eli Lilly and Company
NCT00755807
Efficacy and Safety of Arbaclofen Placarbil in Subjects With Spasticity Due to Multiple Sclerosis
XenoPort
NCT01359566
An Observational Study on Teriflunomide-exposed Pregnancies
Sanofi
NCT03198351
Cognitive Testing for the Pain Quality Assessment Scale (PQAS)
University of Washington
NCT00715598
Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers
Banner Life Sciences
NCT04022473
Safety of Switching From Rituximab to Ocrelizumab in MS Patients
University of Colorado, Denver
NCT02980042
Longitudinal Analysis And Sample Collection To Evaluate PML Risk Host Markers for PML Risk Host Markers for PML Risk
Rocky Mountain MS Research Group
NCT02440126
Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients
Novartis Pharmaceuticals
NCT03623243
Power Over Pain (POP) Study
University of Washington
NCT01800604
Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.
Bayer
NCT01031459
Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical Practice
Novartis Pharmaceuticals
NCT06737419
Comparison of Brain Atrophy Rates, Cognition, and Patient-Reported Outcomes in MS Patients Using Long-term Fingolimod and Glatiramer Acetate
University of Colorado, Denver
NCT02307877
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 33 |
| Phase 3 | 24 |
| Phase 4 | 17 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Sclerosis page
317 registered trials, 120 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 120 Multiple Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Biogen sponsors the most Multiple Sclerosis trials on record, review their full trial history before evaluating a specific study. See Biogen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Sclerosis condition card totals 317 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.